

25 Mar 2021 | Analysis

Device Week, 25 March 2021 – Abernethy To Leave FDA; Dermal Fillers And Adverse Events

by [Ferdous Al-Faruque](#)

This week's podcast tackles US FDA second-in-command Amy Abernethy's surprise announcement that she's leaving the agency. Then, we reveal how an FDA panel thinks dermal fillers like Restylane can be made safer for consumers following a recent uptick in serious adverse events.

Listen to the podcast via the player below:

[Click here to explore this interactive content online](#) 

Medtech Insight articles addressing topics discussed in this episode:

- [FDA's Second-In-Command, Amy Abernethy, Departing Agency](#)
- [US FDA Panel Grapples With Dermal Filler Adverse Events](#)